NTRA - Another large U.S. commercial insurer expands coverage of non-invasive prenatal tests to all singleton pregnancies

Natera (NTRA) announces that the second-largest U.S. commercial insurer has extended coverage of non-invasive prenatal tests ((NIPT)) to all singleton pregnancies. The largest player announced the same several days ago.The expanded coverage bodes well for the company's Panorama molecular test that assesses a baby's risk for severe genetic disorders as early as nine weeks into pregnancy based on a peripheral blood sample. The test also screens twin pregnancies for zygosity and fetal sex of each baby and identifies the risk for more genetic conditions in twin pregnancies than any other NIPT.

For further details see:

Another large U.S. commercial insurer expands coverage of non-invasive prenatal tests to all singleton pregnancies